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Background: Using data from the GenPod trial this study investigates: (i) if depressed individuals with
multiple physical symptoms have a poorer response to antidepressants before and after adjustment for
baseline Beck Depression Inventory II (BDI-II); and (ii) if reboxetine is more effective than citalopram in
depression with multiple physical symptoms.
Methods: Linear regression models were used to estimate differences in mean BDI-II score at 6 and
12 weeks.
Results: Before adjusting for baseline BDI-II, the difference in mean BDI-II score between no and multiple
physical symptoms was 4.5 (95% CI 1.87, 7.14) at 6 weeks, 4.51 (95% CI 1.60, 7.42) at 12 weeks. After
adjustment for baseline BDI-II, there was no evidence of a difference in outcome according to physical
symptoms with a difference in mean BDI-II of 2.17 (95% CI 0.39, 4.73) at 6 weeks and 2.43 (95% CI
0.46, 5.32) at 12 weeks. There was no evidence that reboxetine was more effective than citalopram in
those with multiple physical symptoms at 6 (P¼0.18) or 12 weeks (P¼0.24).
Limitations: Differential non-adherence between treatment arms has the potential to bias estimates of
treatment efﬁcacy.
Conclusion: Multiple physical symptoms predict response to antidepressants, but not after adjustment
for baseline depression severity. Physical symptoms could be a marker of severe depression rather than
an independent prognostic factor and depression should be considered in patients with multiple physical
symptoms. Treatment with reboxetine conferred no advantage over citalopram in those with physical
symptoms, and it is less well tolerated.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Physical symptoms, which are distinct from those considered to
be symptoms of depression (for example sleep and appetite
disturbance) are common in depression (Haug et al., 2004; Bair
et al., 2003). These types of symptoms (for example a change in
bowel habit or pain) are often given as the presenting complaint as
opposed to lowmood (Bridges and Goldberg, 1985; Kirmayer et al.,
1993; Keeley et al., 2004). Depressed patients are 3–7 times more
likely to develop multiple physical symptoms than those who are
not depressed (Hotopf et al., 1998). In many cases, no physical
explanation for these symptoms is found and even when a disease
state is present, the nature or degree of the symptoms may not
correlate with the known pathology. A reduction in clinician's
ability to detect depression has been shown with increasing levels
of such physical symptoms (Bridges and Goldberg, 1985; Kirmayer
et al., 1993; Bair et al., 2003). It has been estimated that 60% of
previously undetected depression cases could have been identiﬁed
if all primary care patients presenting with pain conditions were
examined for possible depression (Katon, 1984). Patients in this
group are therefore at risk of receiving an inaccurate diagnosis
(Kirmayer et al., 1993; Bridges and Goldberg, 1985), are likely
to use more healthcare resources (Bair, 2004; Fritzsche et al., 1999;
Widmer and Cadoret, 1978) and are at risk of potential
iatrogenic harm.
A ‘somatic depression’ has been proposed (Silverstein and
Patel, 2011) that is more prevalent in women. The authors found
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that those who exhibited depression accompanied by multiple
physical symptoms had a poorer response to antidepressants
compared with the other depressed participants. Other studies
have supported the theory that patients who have a depression
with multiple physical symptoms have a poorer outcome in
response to antidepressant treatment (Papakostas et al., 2003;
Papakostas et al., 2008; Bair, 2004; Hoencamp et al., 1994)
problem-solving therapy (Huijbregts et al., 2010) and collaborative
care (Huijbregts et al., 2013). The Papakostas study of 2008 was
a large (n¼570), ﬂexible dose, open-label trial of ﬂuoxetine for
major depressive disorder (MDD, as deﬁned by DSM-IV). Using
a self-report Symptom Questionnaire (Kellner, 1987) they found
that the severity of somatic anxiety symptoms of MDD at baseline
predicted a worse outcome with ﬂuoxetine. The ARTIST study
(Bair, 2004) also demonstrated that pain is a strong predictor of
poor depression outcome.
The association between depression and pain becomes stronger
as the severity of either condition increases (Bair et al., 2003).
Therefore, an alternative theory is that patients with multiple
physical symptoms have a more severe depression at baseline and
therefore a poor prognosis. Denninger et al. (2006) reported that
baseline somatic scores are related to baseline severity of depres-
sion. Severe depression at baseline predicts lower rates of remis-
sion with antidepressant treatment (Rush et al., 2008; Trivedi
et al., 2006). This means that in order to understand the relation-
ship between multiple physical symptoms in depression and
prognosis with antidepressant treatment, the baseline severity of
the depression must be taken in to account and adjusted for in the
analysis. This has not been done in some of the studies that have
predicted a poor outcome for depression with multiple physical
symptoms (Silverstein and Patel, 2011; Papakostas et al., 2003).
Moderators are factors that predict differential treatment
response. Identifying a moderator of antidepressant effect in
patients with multiple physical symptoms has obvious clinical
and economic value (Trusheim et al., 2007). Matching patients to
treatments using particular patient characteristics (such as genetic
polymorphisms or symptom proﬁle) is called stratiﬁed or perso-
nalised medicine. Its beneﬁts have been demonstrated with
a number of anticancer medications (Trusheim et al., 2007).
Psychiatrists commonly select antidepressants based on symptom
proﬁle (Zimmerman et al., 2004), but due to an absence of
established clinical moderators (Simon and Perlis, 2010), there is
limited evidence to inform this choice.
It is thought that brain mechanisms concerned with depression
and pain both involve the monoamine projections from the mid-
brain (Bair et al., 2003). Noradrenaline is implicated in the aetiology
of MDD and has been studied extensively (Ressler and Nemeroff,
1999). There is some evidence to suggest a relationship between
noradrenaline and depression with physical symptoms (Fava, 2003).
Dual acting agents (with an effect on serotonin and noradrenaline)
have been reported as superior to selective serotonin re-uptake
inhibitors (SSRIs) in treating the somatic symptoms associated with
depression (Delgado, 2004; Fishbain, 2000). Kang et al. (2009) found
that venlafaxine (a serotonin–noradrenaline re-uptake inhibitor)
and mirtazipine (a noradrenergic and speciﬁc serotonergic receptor
antagonist antidepressant) improved depressive symptoms in those
with a diagnosis of MDD and somatic symptoms. Based on this
evidence, the presence of physical symptoms could be a moderator
of treatment in those with depression.
Stratiﬁed medicine aims to personalise treatment based on
characteristics of an individual. One way of providing evidence to
stratify antidepressant treatment is to compare two treatments in
a group of patients and see if any particular characteristic
moderates the relationship between treatment and outcome
(18). The GenPoD trial looked at two potential moderators of
response to antidepressants; (1) a polymorphism in the 5HTTLPR
gene (the serotonin transporter gene) (Lewis et al., 2011) and
(2) depression severity (Wiles et al., 2012). There was no evidence
that either moderated treatment response. In this study, we used
GenPod data to investigate the following hypotheses: (1) that
those with multiple baseline physical symptoms do worse with
antidepressant treatment at 6 and 12 weeks; and (2) that rebox-
etine is better than citalopram in treating patients with depression
who have multiple baseline physical symptoms.
2. Methods
2.1. GenPoD trial
This is a secondary analysis of data from the GenPoD trial,
whose trial protocol and main results are published elsewhere
(Lewis et al., 2011; Thomas et al., 2008). In brief, GenPoD is
a multi-centre Randomised Controlled Trial (RCT) conducted in
Bristol, Birmingham and Newcastle, UK. Participants were patients
aged 18–74 years referred to the trial by their General Practitioner
(GP) following agreement to prescribe an antidepressant. Eligibil-
ity criteria included a diagnosis of ICD-10 depressive episode F32
from the Clinical Interview Schedule-Revised (CIS-R) (Lewis et al.,
1992) and a Beck Depression Inventory II (BDI-II) (Beck At, 1961)
score of Z15. Exclusion criteria included having taken an anti-
depressant in the two weeks preceding baseline assessment and
those who could not complete the self-administered scales. The
GPs excluded those with medical contraindications to antidepres-
sant treatment, those with psychosis, bipolar affective disorder or
major substance or alcohol abuse. Chronic physical illness was not
a contraindication to participation.
2.2. Randomisation
Participants were randomised to receive either reboxetine
(4 mg twice daily) or citalopram (20 mg once daily) after giving
informed consent. Randomisation was conducted using a
computer-generated code, centrally administered and communi-
cated by telephone. The randomisation was stratiﬁed by symptom
severity (CIS-R o28 orZ28) and centre using variable block sizes.
Neither participants nor researchers were blinded to allocation.
The researcher gave the medication to the participant. Initially,
those prescribed reboxetine were given a dose of 2 mg twice daily,
which was increased to 4 mg twice daily after four days. Partici-
pants were advised to contact their GP if they wished to increase
their dose.
2.3. Depression measures
The CIS-R was completed at baseline. This is a fully structured
interview measuring common psychological symptoms present in
the week prior to interview. It encompasses 14 symptom groups
with the aim of identifying and characterising the symptoms of
anxiety and depression (Lewis et al., 1992). The BDI-II measures
the severity of depression and was completed at baseline, 6 and
12 weeks.
2.4. Exposure measures
The exposure variable of interest in this study was the presence
of physical symptoms at baseline. This was measured using
a modiﬁed form of the Toronto Side Effects Scale (Vanderkooy
et al., 2002). For this purpose, the scale was used to measure
physical symptoms at baseline before the participants had started
the study medication. The modiﬁed scale used is included in the
supplementary material (Supplementary Fig. 1). Symptoms that
A. Green et al. / Journal of Affective Disorders 163 (2014) 40–46 41
closely resembled symptoms of depression (agitation, daytime
drowsiness and difﬁculty sleeping) were removed from the ana-
lysis since they are included in DSM-IV major depressive episode
criteria (American Psychiatric Association, 2013). Gender-speciﬁc
items (breast swelling, difﬁculty ejaculating and impotence) were
also removed, leaving a total of 24 symptoms. Participants
(n¼601) were grouped into roughly equal quartiles by the number
of physical symptoms they experienced; none (0 physical symp-
toms, n¼161), few (1 physical symptom, n¼126), several (2–3
physical symptoms, n¼156) and multiple (4–16 physical symp-
toms, n¼158) for 4–7 days of the week. Other measures used in
the analysis included Social Support Score from the Psychiatric
Morbidity among Adults Study (Sherbourne and Stewart, 1991),
the AUDIT score for harmful alcohol consumption (Saunders et al.,
1993) and the Short Form Health Survey- 12, a measure of physical
and mental health status (Jenkinson et al., 1997).
2.5. Outcome measures
For the linear regression model, the outcome was BDI-II score
at 6 and 12 weeks, a continuous variable. In order to make the
results comparable to previous studies, a logistic regression model
was also used, In this model, a binary variable of BDI-II of less than
10 was used at 6 weeks, to indicate recovery.
2.6. Statistical considerations
We used linear regression and logistic regression to examine
the hypotheses of this study. Separate models were run at 6 and 12
weeks (linear regression model only). All models were adjusted for
the trial design variables of baseline CIS-R score, medication
allocation and recruitment centre. Further adjustment was made
for the following potential confounders: baseline BDI-II score,
adherence at 6 and 12 weeks, Social Support Score, life events
score, gender, previous history of depression, age, centre, alloca-
tion, harmful alcohol use, baseline anxiety (using the Hospital
Anxiety and Depression scale (Zigmond and Snaith, 1983) and
chronic illness. The regression model included an interaction term
between treatment (citalopram or reboxetine) and number of
baseline physical symptoms to examine whether reboxetine is
more effective than citalopram at treating depression with multi-
ple baseline physical symptoms. As has been previously reported,
age and life events were associated with missing data at 6 weeks
(Wiles et al., 2012; Lewis et al., 2011). These factors were included
in the regression model to investigate the impact of missing data
on our ﬁndings. This method should address any bias under
a missing at random assumption (Carpenter and Kenward, 2004).
Analysis was performed on an intention-to-treat basis.
Details of the sample size calculations for the trial and the
impact of the ﬁnal recruitment ﬁgures on the power of the study
are given elsewhere (Thomas et al., 2008). The GenPoD trial was
adequately powered to address the original questions of the
differential response to treatment and we used conﬁdence inter-
vals to guide our interpretation of the clinical importance of the
results.
3. Results
3.1. Trial participation and follow-up
In the GenPoD trial, 601 participants were randomised to
receive either citalopram (n¼298) or reboxetine (n¼303). At six
weeks, 91% of participants (n¼546) were included in the follow-
up (citalopram: n¼274; reboxetine: n¼272). 81% completed the
twelve week follow-up (n¼486, citalopram: n¼252; reboxetine:
n¼233). Some participants received an increase dosage of their
antidepressant from their GP. For citalopram, 11 had their dosage
increased to 30 mg/day, 33–40 mg/day and 11–60 mg (with one
having an increase to an unknown amount). For reboxetine,
3 increased to 10 mg/day, 9–12 mg/day and one to 16 mg/day.
3.2. Distribution of physical symptoms in the trial population
Fig. 1 shows the distribution of physical symptoms present for
4–7 days in the previous week. The mean number of physical
symptoms experienced for 4–7 days/week was 2.55 (standard
deviation 2.77).
3.3. Baseline comparability of severity groups
Table 1 shows the baseline characteristics of the symptom
quartiles. Individuals in the multiple physical symptoms group
were more likely to be female (73% vs. 61%), report chronic illness
(57% vs. 40%) and had a higher score on the BDI-II (37.94 vs. 29.67)
than individuals with no physical symptoms at baseline.
3.4. Multiple physical symptoms and change in BDI-II score
in response to antidepressants
Table 2 shows adjusted differences in mean BDI-II score
between no physical symptoms and few, several and multiple
physical symptoms at 6 and 12 weeks for all treatments using the
linear regression model. Before adjusting for baseline BDI-II, there
was a large difference in mean BDI-II between no and multiple
physical symptoms, at 6 (4.50 95% CI 1.87, 7.14) and 12 weeks (4.51
95% CI 1.60, 7.42). After adjusting for baseline BDI-II, the CIs
included the null at 6 weeks (2.17 95% CI 0.39, 4.73) and 12
weeks (2.43 95% CI 0.46, 5.32). No other confounders had
a substantial inﬂuence on the association. Fig. 2 shows BDI-II scores
at baseline, 6 and 12 weeks stratiﬁed by physical symptom group.
The logistic regression model also produced no evidence to
suggest that individuals reporting 3 or more physical symptoms at
baseline were less likely to have a BDI score of less than 10 at
6 weeks than individuals with no physical symptoms at baseline
(1.06, 95% CI 0.56, 2.00).
3.5. Citalopram vs. reboxetine in treating depression with multiple
physical symptoms
We tested for an interaction between the physical symptom
group and the randomised treatment, with BDI-II score (a con-
tinuous variable) at 6 and 12 weeks as the outcome. This provided
no evidence that reboxetine was more effective than citalopram in
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Fig. 1. Distribution of physical symptoms present for 4–7 days/week.
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those with multiple physical symptoms, at 6 (interaction P¼0.18)
and 12 weeks (interaction P¼0.24). Table 3 shows mean BDI-II
scores of the citalopram and reboxetine groups at 6 and 12 weeks
by physical symptoms group, adjusted for trial design variables.
When the analysis included factors associated with missing data
(data not shown), the results were consistent with the main
analysis.
4. Discussion
Multiple physical symptoms are associated with poorer
response to antidepressants but we found no evidence for this
relationship after adjusting for depression severity. This is sup-
ported by Denninger et al. (2006) who demonstrated that physical
symptom scores at baseline did not predict reduction in HAM-D
score with treatment, but opposes the ﬁndings of a number other
Table 2
Differences in BDI-II score between no physical symptoms and few, several and multiple physical symptoms at 6 and 12 weeks for all treatments.
None (N¼161) Few (N¼126) Several (N¼156) Multiple (N¼158)
Data at 6 weeks
Unadjusted difference in BDI score at 6 weeksa reference 1.35 (1.28, 3.98) 1.31 (1.23, 3.84) 4.50 (1.87, 7.14)
Adjusted difference in BDI score at 6 weeksb 0.53 (1.97, 3.03) 0.19 (2.61, 2.24) 2.17 (0.39, 4.73)
Adjusted for history of depression 1.32 (1.32, 3.95) 1.25 (1.29, 3.79) 4.46 (1.82, 7.10)
Adjusted for gender 1.28 (1.34, 3.90) 0.96 (1.59, 3.52) 4.16 (1.50, 6.82)
Adjust for life events 1.36 (1.28, 3.99) 1.24 (1.31, 3.78) 4.40 (1.74, 7.06)
Adjust for chronic illness 1.36 (1.26, 3.97) 1.23 (1.30, 3.97) 4.16 (1.52, 6.81)
Adjusted for social support 1.10 (1.49, 3.68) 0.94 (1.55, 3.44) 4.33 (1.74, 6.92)
Adjusted for HAD- anxiety 1.36 (1.24, 3.96) 1.13 (1.38, 3.63) 3.64 (1.00, 6.28)
Adjusted for adherence at 6 weeks 1.24 (1.37, 3.71) 1.19 (1.34, 3.71) 4.47 (1.85, 7.10)
Adjusted for CISR anxiety 0.57 (2.17, 3.33) 1.21 (1.49, 3.92) 3.97 (1.32, 6.61)
Data at 12 weeks
Unadjusted difference in BDI score at 12 weeksa 1.51 (1.42, 4.44) 1.86 (0.93, 4.66) 4.51 (1.60, 7.42)
Adjusted difference in BDI score at 12 weeksb 0.78 (2.05, 3.61) 0.67 (2.05, 3.40) 2.43 (0.46, 5.32)
Adjusted for history of depression 1.32 (1.59, 4.24) 1.63 (1.16, 4.41) 4.25 (1.35, 7.15)
Adjusted for gender 1.38 (1.55, 4.30) 1.46 (1.36, 4.28) 4.13 (1.19, 7.06)
Adjust for life events 1.45 (1.46, 4.37) 1.71 (1.07, 4.50) 3.99 (1.06, 6.93)
Adjust for chronic illness 1.56 (1.33, 4.45) 1.61 (1.16, 4.37) 3.74 (0.84, 6.65)
Adjusted for social support 1.30 (1.58, 4.18) 1.35 (1.41, 4.11) 4.16 (1.29, 7.04)
Adjusted for HAD- anxiety 1.56 (1.34, 4.46) 1.65 (1.12, 4.42) 3.70 (0.77, 6.63)
Adjusted for adherence at 12 weeks 1.56 (1.37, 4.50) 1.88 (0.92, 4.68) 4.58 (1.66, 7.51)
Adjusted for CISR anxiety 12 weeks 0.62 (2.44, 3.69) 2.23 (0.77, 5.23) 3.55 (0.61, 6.48)
BDI (Beck Depression Inventory), CIS-R (Clinical Interview Schedule-Revised), HAD (Hospital Anxiety and Depression scale).
a Adjusted for trial variables.
b Adjusted for baseline BDI-II.
Table 1
Characteristics of participants, according to baseline physical symptoms.
Overall (N¼601) None (N¼161) Few (N¼126) Several (N¼156) Multiple (N¼158)
Mean age (SD) 38.82 (12.35) 38.16 (11.05) 39.88 (12.65) 38.21 (12.31) 39.27 (13.40)
N (%) female 408 (67.87) 98 (60.87) 77 (61.11) 119 (76.28) 114 (72.15)
N (%) CIS-R 4¼28 394 (65.56) 73 (45.34) 75 (59.52) 105 (67.31) 141 (89.24)
Mean BDI tot (SD) 33.67 (9.70) 29.67 (8.37) 32.68 (8.70) 34.27 (9.33) 37.94 (10.17)
Mean life events score (SD) 1.67 (1.30) 1.44 (1.27) 1.42 (1.16) 1.81 (1.42) 2.00 (1.48)
Mean social support score (SD) 12.02 (3.80) 12.51 (3.50) 11.80 (3.99) 11.74 (3.77) 11.96 (3.94)
N (%) taking citalopram 298 (49.60) 81 (50.31) 58 (46.03) 84 (53.85) 75 (47.47)
N (%) in full time work 243 (40.43) 70 (43.48) 55 (43.65) 56 (35.90) 62 (39.24)
N (%) with no previous depression 167 (27.80) 49 (30.63) 33 (26.19) 42 (26.93) 41 (25.95)
Mean anxiety symptoms on CIS-R (SD) 2.49 (1.47) 2.11 (1.50) 2.24 (1.32) 2.37 (1.51) 2.94 (1.41)
Mean AUDIT score (alcohol use) (SD) 4.01 (3.70) 4.09 (3.04) 4.00 (3.89) 4.19 (3.88) 3.76 (3.85)
N (%) chronic illness 288 (47.92) 64 (39.75) 53 (42.06) 81 (51.92) 90 (56.96)
Mean HAD anxiety score (SD) 13.22 (3.57) 12.06 (3.42) 12.59 (3.37) 13.19 (3.65) 14.95 (3.12)
Mean HAD depression score (SD) 12.6 (4.00) 11.55 (3.76) 12.12 (3.71) 12.49 (4.02) 14.16 (4.00)
Number of Caucasians (%) 575 (95.67) 158 (98.14) 115 (91.27) 152 (97.44) 150 (94.94)
SD (standard deviation), BDI (Beck Depression Inventory), CIS-R (Clinical Interview Schedule-Revised), HAD (Hospital Anxiety and Depression scale).
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studies (Silverstein and Patel, 2011, Papakostas et al., 2004; Bair,
2004; Keeley et al., 2004; Papakostas et al., 2003; Hoencamp et al.,
1994).
There are some possible explanations for our ﬁndings. Multiple
physical symptoms may represent severe depression and could be
a sign of more severe illness. It could be that the severity of
depression associated with multiple physical symptoms confers
poor prognosis rather than the physical symptoms themselves.
This is consistent with earlier theories on predictors of antide-
pressant response, whereby biological symptoms were used as
a marker of depression severity (Delgado, 2004). It is possible
multiple physical symptoms represent a misinterpretation of
physical sensations, that is more likely to occur in depression
and would usually be ignored by someone without depression.
Therefore the more severe the depression, the more extreme the
experience of physical symptoms.
An alternative theory is that increased physical symptoms are
associated with an underlying physical condition that leads to
poor health and consequently depression. Inﬂammatory processes
have been implicated in this relationship (Raison et al., 2006).
In our study, adjusting for chronic illness made little difference to
the difference in mean BDI-II score between no and high scores at
6 weeks (4.16 95% CI 1.52, 6.81 vs. 4.50 95% CI 1.87, 7.14) and only
a small difference at 12 weeks (3.74 95% CI 0.84, 6.65vs. 4.51 95% CI
1.60, 7.42).
Contrary to our ﬁndings, other large RCTs (Bair, 2004; Silverstein
and Patel, 2011; Papakostas et al., 2003; Papakostas et al., 2008;
Hoencamp et al., 1994; Keeley et al., 2004), have demonstrated that
the presence of physical symptoms at baseline predicts an increased
likelihood of non-response to an antidepressant. There are several
possible explanations for this involving the method of data collection
and/or data analysis. The most important difference is that some of
these studies did not control for baseline severity of depression
(Silverstein and Patel, 2011; Papakostas et al., 2003). Therefore, those
individuals with a poor prognosis who had more somatic symptoms
could have been more severely depressed in the ﬁrst place.
We used a modiﬁed version of the Toronto Side Effects Scale
(Vanderkooy et al., 2002) to measure physical symptoms. This is
a broad screening tool encompassing different types of physical
symptoms in multiple modalities. The Kellner symptom question-
naire (Kellner, 1987) used by Papakostas (Papakostas et al., 2008,
2003) and the SCL-90 (Derogatis et al., 1973) used byHoencamp
et al. (1994) and Papakostas et al. (2008), include symptoms of
depression such as poor appetite, and anxiety symptoms such as a
choking feeling or hot spells. Keeley et al. (2004) have considered
DSM-IV physical complaints associated with depression, general-
ised anxiety disorder and panic disorder as their measure of
baseline physical symptoms. We excluded any symptoms that
resembled well- established somatic symptoms of depression
(for example, insomnia) and adjusted for anxiety in our analysis
using a scale that avoided asking about the physical symptoms of
anxiety (to prevent overcorrection) in case this was a confounder.
Our data demonstrated that baseline anxiety was not a confounder
but other studies have not done this (Silverstein and Patel, 2011;
Papakostas et al., 2008). One possible explanation for these
contradictory ﬁnding could be that the physical symptoms scale
used in prior studies had an overlap with symptoms of depression.
Papakostas and colleagues (Papakostas et al., 2008) demon-
strated an association between multiple physical symptoms and
treatment response even after adjusting for baseline depression
severity, and our study does not. It is difﬁcult to fully explain this
difference. As they have not presented their data before adjusting
for baseline depression, we do not know what contribution this
has made to the results. This makes their results hard to interpret.
The association they found between baseline somatic scores and
treatment response (OR 0.96 95% CI 0.94–0.98, P¼0.002) was
statistically signiﬁcant. Since a 3-point difference in the BDI-II
score corresponds to a minimally important clinical difference
(NICE guidelines, 2004), this difference may not have clinical
relevance. Similarly, our 95% CIs indicate that individuals reporting
multiple physical symptoms at baseline may score up to 4 points
higher on the BDI at 6 (2.17, 95% CI 0.39, 4.75 and 12 weeks
(2.43, 95% CI 0.46, 5.32), which may also not be of clinical
relevance.
There was no evidence of a difference between citalopram and
reboxetine in treating depression with multiple baseline physical
symptoms and no evidence that physical symptoms are a moderator
of the antidepressant effect of SSRIs and NARIs. Using data from the
GenPod trial, Wiles et al. (2012) also found that treatment with NARIs
did not confer any advantage over SSRI treatment for outcome in those
with more severe depression. Therefore, noradrenergic antidepres-
sants do not appear to be superior to serotonergic antidepressants in
treating depression in those with multiple physical symptoms or those
with more severe depression in this primary care population. Since
reboxetine was associated with more adverse effects and more drop-
outs (Cipriani et al., 2009; Crawford et al., 2014), this suggests that
other agents should take preference over a NARI.
The GenPoD trial is a suitable data set to address both our
hypotheses. Data were collected from primary care patient with
a diagnosis of severe depression (mean baseline BDI was 33.7).
It compared two different classes of antidepressants to see
whether a speciﬁc patient characteristic moderates the relation-
ship between treatment type and outcome. This is an appropriate
way of testing for a moderator effect (Simon and Perlis, 2010).
Secondary analysis testing for moderation can suffer from low
power (Brookes et al., 2004; Brown, 1988), but since the GenPod
study was originally designed to test for an interaction effect, this
was not a major issue in this case, and indeed in the event the
conﬁdence intervals were relatively narrow.
5. Limitations
There are a few limitations to this study. Follow-up data were
available for 81% of trial participants at 12 weeks. Even a small
amount of missing data has the potential to introduce bias;
however, adjustment for factors associated with missing data
produced results consistent with our main analysis.
Table 3
Mean BDI-II scores of the citalopram and reboxetine groups as randomised, at 6 and 12 weeks by physical symptoms group, adjusted for trial variables.
Overall (N¼601) None (N¼126) Few (N¼131) Several (N¼148) Multiple (N¼196)
BDI at 6 weeks for citalopram (SD) 18.87(10.82) 16.88 (9.37) 18.13 (9.88) 17.64 (11.00) 22.89 (11.92)
BDI at 6 weeks for reboxetine (SD) 19.58 (11.47) 16.95 (10.05) 19.13 (10.96) 20.00 (11.11) 22.26 (11.94)
Adjusted difference between citalopram and reboxetine at 6 weeks (SE) NA 1.01 (1.42) 0.75 (1.88) 3.14 (1.91) 1.11 (1.83)
BDI at 12 weeks for citalopram (SD) 15.38 (11.47) 13.62 (9.43) 14.58 (9.88) 13.24 (10.62) 20.29 (14.17)
BDI at 12 weeks for reboxetine (SD) 15.09 (11.29) 11.87 (9.12) 14.51 (9.50) 17.41(12.65) 16.50 (12.50)
Adjusted difference between citalopram and reboxetine at 12 weeks (SE) NA 0.66 (1.54) 0.07 (1.88) 4.9 (2.10) 3.77 (2.23)
BDI (Beck Depression Inventory), SD (standard deviation), SE (standard error).
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More participants allocated to reboxetine discontinued anti-
depressant treatment than those allocated to citalopram (36% vs.
17% at 6 weeks) (Crawford et al., 2014). This is consistent with the
meta-analysis ﬁndings of Cipriani et al. (2009). Non-adherence to
treatment, particularly differential non-adherence between treat-
ment arms, has the potential to bias estimates of treatment
efﬁcacy. The reboxetine group suffered more adverse effects, but
there was not strong evidence of an association between adverse
effects and drop-out. 42% of participants had discontinued their
medications at 12 weeks. A lack of blinding may have introduced
a source of bias as the participants knew which drug they were
receiving. However, the participants would have required strong
preconceptions on the effectiveness of each drug and so this is
unlikely to have inﬂuenced the results. Despite the relatively large
sample size it is possible that we did not have sufﬁcient power to
detect interactions, which may have resulted in type II errors;
however, we have used the conﬁdence intervals obtained to guide
interpretation in respect of potential clinical importance.
Finally, trial participants themselves are often a highly selected
group, which can lead to issues of generalisability. On the other
hand, participants were recruited from primary care, and the study
included those with chronic physical illness, which is likely to
increase the generalisability of the ﬁndings. Moreover, the analysis
adjusted for chronic illness, baseline depression and anxiety as
well as other potential confounders.
6. Conclusions
Multiple baseline physical symptoms appear to predict poor
response to antidepressants, but not after adjustment for depres-
sion severity. Multiple physical symptoms may represent severe
depression rather than a poor prognostic factor. Clinicians should
ask about mood symptoms and explore psychosocial issues in
patients with multiple physical symptoms. If considering a diag-
nosis of depression in someone with multiple physical symptoms,
clinicians should treat it as a moderate to severe depression. This is
essential in order to avoid inappropriate investigation and treat-
ment of physical symptoms, which could lead to iatrogenic harm.
Reboxetine does not confer any advantage over citalopram in this
group, and it is less well tolerated. Since there is no evidence that
physical symptoms are a moderator of treatment in patients with
multiple physical symptoms when a clinician chooses an anti-
depressant they should take account of the side effect proﬁle,
rather than depend on physical symptoms.
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